A noted philanthropist and businessman, Warren Lammert functions as the CEO and chief investment officer of Granite Point Capital, a Boston hedge fund that he founded. Warren Lammert also co-founded Tevard Biosciences, a startup that develops innovative gene therapies to treat rare conditions.
A process that introduces new genetic material into the body’s cells to block the effects of abnormal genes, gene therapy holds a lot of potential for improving therapies and treatments for genetic disorders, cancer, and other diseases. A recent study published in Science Translational Medicine reported that researchers were able to edit the genetic makeup of a specialized subset of adult blood stem cells for the first time.
The study’s findings suggest that there may be a more efficient way to modify stem cells, a process that has the potential to significantly reduce the costs of gene-editing treatments for blood disorders and other diseases, as well as the negative side effects. “Targeting this portion of stem cells could potentially help millions of people with blood diseases,” said senior study author Dr. Hans-Peter Kiem, a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center.
A process that introduces new genetic material into the body’s cells to block the effects of abnormal genes, gene therapy holds a lot of potential for improving therapies and treatments for genetic disorders, cancer, and other diseases. A recent study published in Science Translational Medicine reported that researchers were able to edit the genetic makeup of a specialized subset of adult blood stem cells for the first time.
The study’s findings suggest that there may be a more efficient way to modify stem cells, a process that has the potential to significantly reduce the costs of gene-editing treatments for blood disorders and other diseases, as well as the negative side effects. “Targeting this portion of stem cells could potentially help millions of people with blood diseases,” said senior study author Dr. Hans-Peter Kiem, a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center.
